HALO News and Press, Halozyme Therapeutics Inc. From 01/09/23

Summary The stock of Halozyme Therapeutics, Inc. has moved up nicely in recent months, buoyed by solid third quarter results and positive commentary from the analyst firm community. However, Halozyme stock is hitting up against some price targets and insiders have notably started to sel...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer...

Summary Smallcaps are the first ones to get affected by the recession and the last ones to show recovery. Key fundamental drivers of the VTWO ETF are rising interest rates, recession, and overall bearish sentiments of the markets. My technical analysis framework based on Trend Flow,...

Morgan Stanley has initiated Halozyme Therapeutics ( NASDAQ: HALO ) at overweight citing the company's Enhanze technology used for subcutaneous administration of therapies that is licensed to companies. The firm has a $65 price target (~15% upside based on Tuesday's close). Analys...

Halozyme (HALO) has always had a story that’s easy to love, as its Enhanze drug delivery technology allows huge-selling treatments to be delivered intravenously in far less time than usual, saving tons of time, money and adding convenience, too, explains Mike Cintolo, editor of Cabot Growt...

S&P 500 is breathing a much-awaited sigh of relief after the monthly inflation data came in better than expected ( read more ). But there’s hardly a reason to believe that it’s not just another one of the bear market rallies, says Dutch Masters – the Fou...

Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of its management team are scheduled to present and host inv...

Halozyme Therapeutics, Inc. (HALO) Q3 2022 Earnings Conference Call November 08, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBros...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation